Skip to main content

Technical Note Evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass campaigns November 2016

Background


Three oral cholera vaccines (OCVs) are currently pre-qualified by WHO: Dukoral, Shanchol, and Euvichol All are oral killed whole-cell (WC) vaccines that provide sustained protection of >50% for at least two years in endemic populations, induce an immune response relatively quickly (7-10 days after the 2nd dose) and have a good safety profile. Shanchol has demonstrated longer term protection – 65% over five years – as compared to Dukoral. On the other hand, Dukoral has been shown to provide better short-term protection against cholera, particularly among children 2-5 years old and also confers significant short-term protection against ETEC (≈50% for three months). Shanchol and Euvichol have the same formulation and comparable safety and immunogenicity profiles.  Both are reformulated versions of Dukoral without the B subunit of the cholera toxin (no need for buffer). All three vaccines have a two-dose regimen with doses given between one and six weeks apart (three doses for Dukoral in children aged 2–5 years).

Subscribe our newsletter

Subscribe to update news from us
The subscriber's email address.